MARKET

ORXOY

ORXOY

Orexo Ab
OTCQX
1.770
-0.350
-16.51%
Opening 09:54 07/21 EDT
OPEN
1.770
PREV CLOSE
2.120
HIGH
1.770
LOW
1.770
VOLUME
400
TURNOVER
708
52 WEEK HIGH
4.050
52 WEEK LOW
1.720
MARKET CAP
57.84M
P/E (TTM)
0.663
1D
5D
1M
3M
1Y
5Y
1D
Orexo publishes transcript of Q2 2026 earnings call
PUBT · 5d ago
Orexo Q2 FY26 net loss widens to SEK 102.5 million; revenue falls to SEK 3.5 million
PUBT · 5d ago
BRIEF-Orexo Q2 EBIT SEK -103.3 Million
Reuters · 5d ago
Orexo to present Q2 interim report in investor webcast and teleconference
PUBT · 07/10 09:03
Orexo names Raheleh Nassaji SVP business development, adds her to management team
PUBT · 06/09 06:00
OREXO AB - SINGLE NASAL DOSE OF OX390 ACHIEVES TARGETED THERAPEUTIC EXPOSURE
Reuters · 05/19 12:58
Orexo reports positive in-vivo study data for OX390 nasal atipamezole absorption
PUBT · 05/19 06:07
Orexo AGM re-elects Friedrich von Bohlen und Halbach as board chair
PUBT · 05/07 15:03
More
About ORXOY
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.

Webull offers Orexo AB - ADR stock information, including OTCQX: ORXOY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORXOY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ORXOY stock methods without spending real money on the virtual paper trading platform.